![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, September 02, 2021 8:10:24 AM
“The data from this Phase I trial show that XPro decreases biomarkers of neuroinflammation and nerve cell death while improving biomarkers of neurorepair in patients with AD,” stated RJ Tesi, M.D., CEO of INmune Bio
Recent INMB News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:05:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:30:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:00:11 PM
- INmune Bio Inc. to Join Russell 3000® Index • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/29/2024 08:05:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:10:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:10:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:08:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:08:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:07:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 08:00:14 PM
- INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:05:36 PM
- INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/25/2024 01:00:00 PM
- INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update • GlobeNewswire Inc. • 03/28/2024 08:01:53 PM
- INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 • GlobeNewswire Inc. • 03/26/2024 08:01:00 PM
- INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™ • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/12/2024 02:00:00 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM